News
Publications
Multimedia
Conferences
Webcasts
Resources
Subscribe

Spotlight -

Drug Development|

Quality Systems

Hafez Abdel-Kader

Hafez Abdel-Kader is a director at Sanofi.

Articles by Hafez Abdel-Kader

Analytical Method Comparability in Registration and Post-Approval Stages: A Risk-Based Approach

ByFrank Diana,Jeff Hofer,Marion Chatfield,Nancy Benz,Yuan Huang,Mark Argentine,Qinggang Wang,Shreekant Karmarkar,Hafez Abdel-Kader,Lakshmy M. Nair,Hui Fang,Theresa Natishan,Andrea M. Pless,Rick Burdick,Zeena Williams

October 2nd 2014

A risk-based approach is recommended for analytical method comparability for HPLC assay and impurities methods.

Latest Updated Articles

Analytical Method Comparability in Registration and Post-Approval Stages: A Risk-Based Approach
Published: October 2nd 2014 | Updated:

Trending on Pharmaceutical Technology

Integrating Sustainability into the Core of Pharmaceutical Science

Outsourcing Partners Providing End-to-End Service

Kimberly-Clark to Buy Tylenol Maker Kenvue: Analyzing Risks and Rewards

© 2025 MJH Life Sciences^®

All rights reserved.